Publication details
Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | European Journal of Haematology |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | thalidomide; monotherapy; multiple myeloma; treatment; relapse |
| Description | Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM). The optimal dosing regimen of thalidomide is not known. Patients and Methods: We retrospectively analysed the overall response rate and response duration of 53 patients with relapsed MM who received thalidomide in a median dose of 100 mg daily. The aim of the study was to compare the response rates of thalidomide given as the second-line treatment to those of thalidomide given as the third-line therapy. |